ArticleAdvances in therapy2023

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.

Christopher Parker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.